Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichlorodiammino platinum(II) in mice bearing Lewis lung carcinoma.
The effects of square planar rhodium, [RhacacCOD]o and iridium, [IracacCOD]o complexes and of octahedral ruthenium, [cis-RuCl2 (DMSO)4]o complex have been examined in comparison with cis-dichlorodiammino platinum(II) (cis-PDD). The toxicity in BDF1 mice varies widely and decreasing LD50-values, ranging from 0.94 mg/kg to 1000 mg/kg, have been obtained for cis-PDD, [RhacacCOD]o, [IracacCOD]o and [cis-RuCl2(DMSO)4]o, respectively. All the tested complexes similarly inhibit the growth of subcutaneous Lewis lung carcinoma and the development of spontaneous as well as of artificial metastases, with the exception of [IracacCOD]o which is inactive on metastases. The antitumor activity of [RhacacCOD]o and [cis-RuCl2(DMSO)4]o appears interesting, since it is of the same magnitude as that of cis-PDD, considering also that they were found to be only marginally nephrotoxic.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D002945:Cisplatin / Q000627:therapeutic use*; D007495:Iridium / Q000627:therapeutic use*; D007928:Lethal Dose 50; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009942:Organometallic Compounds / Q000627:therapeutic use*; D012238:Rhodium / Q000627:therapeutic use*; D012428:Ruthenium / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; C038741:dichlorotetrakis(dimethyl sulfoxide)ruthenium II; C038740:acetylacetonate-1,5-cyclooctadiene iridium I; C038739:acetylacetonate-1,5-cyclooctadiene rhodium I; D007495:Iridium; D012428:Ruthenium; D012238:Rhodium; D002945:Cisplatin